Search | GSK

Singapore

Locations

GSK Singapore

https://www.gsk.com/en-gb/locations/singapore/

First published: 18 February 2025

GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE

Media

Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta

https://www.gsk.com/en-gb/media/press-releases/gsk-announces-positive-results-in-fourth-consecutive-pivotal-trial-of-benlysta-belimumab-in-sle/

First published: 13 November 2016

ViiV Healthcare begins phase III programme with dolutegravir/rilpivirine combination for HIV maintenance therapy

Media

ViiV announced the start of a phase III clinical trial for the safety and efficacy of dolutegravir&rilpivirine for adult patients with HIV.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-begins-phase-iii-programme-with-dolutegravirrilpivirine-combination-for-hiv-maintenance-therapy/

First published: 06 May 2015

GSK and Save the Children launch 2015 call for developing country healthcare innovations to reduce child deaths

Media

GSK and Save the Children announce the launch of their third annual $1 million Healthcare Innovation Award.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-save-the-children-launch-2015-call-for-developing-country-healthcare-innovations-to-reduce-child-deaths/

First published: 15 July 2015

GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension

Media

GSK receives CHMP positive opinion to expand indication for Volibris® in pulmonary arterial hypertension

https://www.gsk.com/en-gb/media/press-releases/gsk-receives-chmp-positive-opinion-to-expand-indication-for-volibris-in-pulmonary-arterial-hypertension/

First published: 23 October 2015

GSK’s Advair® Diskus® achieves primary endpoint in LABA safety study of patients with asthma

Media

GlaxoSmithKline plc (GSK) today announced results from the ‘LABA’ (long acting beta2-agonist) safety study, AUSTRI (SAS115359).

https://www.gsk.com/en-gb/media/press-releases/gsk-s-advair-diskus-achieves-primary-endpoint-in-laba-safety-study-of-patients-with-asthma/

First published: 27 October 2015

GSK receives European marketing authorisation to expand indication for Volibris® in treatment of pulmonary arterial hypertension

Media

GSK today announced that the European Commission has approved a variation to expand the current therapeutic indication for Volibris®

https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-to-expand-indication-for-volibris-in-treatment-of-pulmonary-arterial-hypertension/

First published: 24 November 2015

GSK and Theravance announce positive results from studies comparing ANORO™ ELLIPTA™ with SERETIDE® DISKUS® and ADVAIR® DISKUS® in patients with COPD

Media

GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced positive results from three phase III studies.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-results-from-studies-comparing-anoro-ellipta-with-seretide-diskus-and-advair-diskus-in-patients-with-copd/

First published: 14 March 2014

ViiV Healthcare announces new collaboration with Janssen to investigate single-tablet regimen for maintenance treatment of HIV-1

Media

ViiV announced they have entered into an agreement with Janssen for the development and commercialisation of Tivicay® Edurant®.

https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-collaboration-with-janssen-to-investigate-single-tablet-regimen-for-maintenance-treatment-of-hiv-1/

First published: 12 June 2014

GSK and Amicus Therapeutics announce revised Fabry agreement

Media

GSK & Amicus announced that Amicus has obtained global rights to develop chaperone migalastat HCl as monotherapy for Fabry disease.

https://www.gsk.com/en-gb/media/press-releases/gsk-and-amicus-therapeutics-announce-revised-fabry-agreement/

First published: 20 November 2013